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Tyrosinemia type 1 patients: a systematic
review
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Paul Sutcliffe1 and Sian Taylor-Phillips1*
Abstract
Background: Tyrosinemia type 1 (TYR1) is a rare autosomal recessive disorder of amino acid metabolism that is
fatal without treatment. With medication (nitisinone) and dietary restrictions outcomes are improved. We conducted a
systematic review to investigate if treatment with nitisinone following screening provides better long-term outcomes
than treatment with nitisinone following symptomatic detection.
Methods: We searched Web of Science, Medline, Pre-Medline, and Embase up to 23rd September 2016 for journal
articles comparing clinical outcomes of TYR1 patients receiving earlier versus later nitisinone treatment. Two reviewers
independently screened titles and abstracts, assessed full texts, and appraised study quality. Data extraction was
performed by a single reviewer and checked by a second.
Results: We included seven articles out of 470 unique records identified by our search. The seven articles included four
studies (three cohort studies and one cross-sectional study). Study sample sizes ranged from 17 to 148. There is
consistent evidence that nitisinone is an effective treatment for TYR1, and some evidence that earlier treatment with
nitisinone and dietary restrictions within the first one or 2 months of life is associated with reduced need for liver
transplantation, lower rates of renal dysfunction, fewer neurological crises, and fewer, shorter hospital admissions
compared to later treatment. However, study quality was moderate to weak, with high risk of confounding and
applicability concerns to the screening context. We conducted post hoc analyses to address these issues. Results
suggested an association between earlier treatment and fewer liver transplants (earlier treatment: 0% of 10–24 patients;
later treatment: 25–60% of 4–15 patients), but no impact on neurological crises. We found no effect of treatment
timing on mortality in either the primary or post hoc analyses. Post hoc analyses of other health-related outcomes
were not possible because of sample size or reporting.
Conclusions: There is some evidence from observational studies that earlier treatment with nitisinone might be
beneficial but this is subject to bias. The applicability of our findings to the screening context or clinical practice is
limited as not all early-treated patients were identified by screening and late-treated groups included patients born
prior to the availability of nitisinone.
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Background
Tyrosinemia type 1 (TYR1, OMIM 276700) is a rare
autosomal recessive disorder of amino acid metabolism
that is caused by a defect in the final enzyme of the
pathway of tyrosine degradation, namely fumarylacetoace-
tate hydrolase (FAH) [1]. About one person in 100,000 is
affected with TYR1 globally, but incidence is more com-
mon in some regions, notably in Québec [2]. Ninety-five
mutations have been described so far in TYR1 with differ-
ent geographical and ethnic distributions [3]. Deficiency
of FAH causes an accumulation of tyrosine and toxic
metabolites succinylacetone (SUAC), maleylacetoacetate
and fumarylacetoacetate [4]. TYR1 mainly affects the liver,
kidneys and peripheral nerves [1]. Two extreme clinical
phenotypes have been described: an “acute” form with
symptoms starting during the first few months of life and
early severe liver failure, and a “chronic” form resulting in
more gradual liver disease and increased risk for hepato-
cellular carcinoma [2]. Clinical presentations can be vari-
able, even in cases with the same underlying mutation [5].
The age at onset of symptoms broadly correlates with se-
verity [6]. Without treatment, death from liver failure and
recurrent bleeding, neurological crisis or hepatocellular
carcinoma frequently occurs before the age of 10 years [7].
Until the early 1990s, the only strategies available to
manage the symptoms of TYR1 were protein-restricted
diets (usually low in phenylalanine, methionine and tyro-
sine) and liver transplantation. The efficacy of these
strategies is variable. For example, 1-year survival rates
of 51% have been reported for children placed on a re-
stricted diet before 6 months of age [7], and 90% for
those undergoing liver transplantation [8]. In 1992, an
alternative treatment, nitisinone, was introduced [9].
Nitisinone inhibits 4-hydroxyphenylpyruvate dioxygen-
ase, an enzyme that is upstream of FAH in the tyrosine
degradation pathway, and reduces the formation of toxic
metabolites. Studies have suggested that the treatment
can have dramatic benefits, including normalisation of
renal dysfunction, control of liver failure in up to 90%
individuals, the reduction or even elimination of neuro-
logical crises, and survival into adulthood [10–13].
An apparent benefit of earlier versus later treatment
has been reported in a number of cohort studies (i.e. from
Québec [10] and the UK [14]). To justify the introduction
of newborn blood spot (NBS) screening programmes for
TYR1, there should be evidence that, next to a simple,
safe, precise and validated screening test, treatment at a
pre-symptomatic phase leads to better outcomes for the
screened individual compared to treatment initiation
following symptomatic detection. We have recently
published a linked review regarding the current state of
evidence relating to the test accuracy of newborn screening
for TYR1 using SUAC as primary marker that highlights
important limitations in the literature [15]. To date, no
study has synthesized and quality appraised all of the
available evidence regarding early and late treatment of
TYR1 with nitisinone. Therefore, the aim of this review
was to compare the outcomes of TYR1 patients with
early (pre-symptomatic) nitisinone treatment to later
(following symptomatic detection) nitisinone treatment
in a systematic review to assess the question of early
treatment benefit from a screening perspective.
Methods
The protocol is registered at the PROSPERO Inter-
national Prospective Register of Systematic Reviews
(CRD42015026912).
Search strategy
Systematic literature searches were undertaken in Web
of Science (Core Collection), Medline (Ovid), Medline
In-Process & Other Non-Indexed Citations (Ovid), and
Embase (Ovid). We searched for terms relating to tyrosi-
nemia and nitisinone (the full electronic search strategy
can be found in Additional file 1). We also examined the
reference lists of included studies and of previous re-
views. Individuals and organisations were contacted for
studies that were not in the public domain. The search
was conducted on 14th September 2015 and updated on
23rd September 2016. No date limits were applied for
the original search.
Eligibility
English language journal articles which investigated people
who have TYR1 comparing early (following screening)
versus late (following presentation with symptoms) nitisi-
none treatment were included. Diagnosis of TYR1 in the
early treated patients was following universal newborn
screening, cascade testing or incidental detection during
newborn screening for phenylketonuria (PKU). All out-
comes of the treatment were recorded. Exclusion criteria
were non-human studies, papers not available in English
language, and letters, editorials and communications, grey
literature or conference abstracts.
Study selection and data extraction
Screening of titles and abstracts and full text assessment
was conducted independently by two reviewers. Data ex-
traction was performed by a single reviewer, and all data
extraction forms were checked by a second reviewer.
Disagreements at each stage were resolved by consensus,
with the involvement of third reviewer when required.
Quality appraisal
Quality appraisal was undertaken independently by two
reviewers using the Effective Public Health Practice Pro-
ject (EPHPP) quality assessment tool for quantitative
studies [16] (see Additional file 1). The tool covers six
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domains: selection bias, study design, confounders, blind-
ing, data collection methods, withdrawals & dropouts. Each
domain is rated as weak, moderate, and strong quality. A
global score is determined on the basis of these ratings:
weak (two or more weak domains), moderate (one weak
domain), strong (no weak domains). Disagreements
were resolved by consensus, with the involvement of
third reviewer when required.
Data summary and synthesis
A narrative synthesis of study characteristics and out-
comes in terms of mortality, liver disease and transplant-
ation, renal dysfunction and rickets, hospital admissions
and neurocognitive outcomes is provided for all included
studies.
To address concerns about the applicability of in-
cluded studies to the screening perspective as well as
possible confounding factors, three post-hoc compari-
sons were explored. The aim was to a) summarise the
findings which are most applicable to the question of
the benefit of screening using comparison 1 below (ex-
cluding patients who did not receive nitisinone immedi-
ately after diagnosis), and b) to summarise comparisons
corrected for the bias of systematic variation in disease
severity by excluding cases in comparisons 2 and 3
below. The following three post hoc analyses considered
different subsets of the available individual patient data
of the included studies:
1) Nitisinone treatment immediately following
diagnosis in screen-detected versus symptomatically
presenting cases. This is the comparison of most
interest when considering what the benefits of
implementing screening may be, but may be biased
in favour of screening if screening detects milder
spectrum of disease.
2) Nitisinone treatment immediately following
diagnosis in early (<2 months) symptomatically
presenting versus late (≥2 months) symptomatically
presenting cases. Whilst less applicable to the
screening question, this comparison is not biased in
favour of early detection as the spectrum of disease
in early presenting cases will be the same or more
severe.
3) Direct (<1 month) nitisinone initiation versus
delayed nitisinone initiation (within a time frame
most TYR1 patients present symptomatically;
1–12 months) following screen detection. Whilst
also less applicable to the screening question, this
comparison is not biased in favour of early detection
as the test detects the same spectrum of disease.
In the post hoc analyses, proportions between two
groups were compared using the chi-square test; in cases
of expected values smaller than five, a Fisher exact test
was used.
Results
Searching, sifting, and sorting
Our electronic searches identified 470 unique records of
which 50 full text articles were assessed (Fig. 1). Of these,
43 articles were excluded using the pre-defined inclusion/
exclusion criteria (see Additional file 1 for excluded stud-
ies with reason). The remaining seven articles (reporting
data from four studies) met the inclusion criteria and were
included in the narrative synthesis.
Characteristics of included studies
The main characteristics of studies included are sum-
marised in Table 1. Three cohort studies (Birmingham
study [12, 14, 17], Québec study [10, 11] and one inter-
national cohort [18]) and one cross-sectional study [19]
published in seven papers reported on clinical outcomes
in early versus late nitisinone-treated TYR1 patients.
Data were collected retrospectively in the international
cohort [18], in two papers from the Birmingham study
[12, 14], and in one paper from the Québec study [11].
Data were collected prospectively in one paper from the
Birmingham study [17], while both prospective and
retrospective data were collected in the other paper from
the Québec study [10] and the cross-sectional study
[19]. The number of TYR1 patients included in the ana-
lyses ranged from 17 from a single centre in the UK [14]
to 148 from 21 centres in Europe, Turkey and Israel
[18]. There was a high overlap in included TYR1 cases
between the two published papers from the Québec
study [10, 11] with 78 of 95 patients (82%) included in
both. TYR1 cases included in the three papers of the
Birmingham (UK)-based study [12, 14, 17] overlapped
widely. The TYR1 cases from Birmingham were possibly
also included (at least in part) in the international cohort
study [18] and in the multicentre, cross-sectional study
[19]. Definition of ‘early’ and ‘late’ nitisinone treatment
varied between the studies: in the Québec study, all
early-treated patients were detected by universal new-
born screening and nitisinone treatment was started be-
fore 30 days [10] or 4 weeks of age [11]. In the
Birmingham (UK)-based study, the early treatment
group mainly consisted of patients identified by cascade
testing or coincidentally during routine PKU screening,
with nitisinone treatment initiated before 2 months (10/11
screen-detected, one presenting with symptoms at the age
of 1 month) [17], before 52 days (all screen-detected) [14]
and before 2 weeks of age (all screen-detected) [12], re-
spectively. The international cohort by Mayorandan et al.
defined early treatment as nitisinone started before 1
month of age, but it was unclear if all patients were
identified pre-symptomatically by screening [18]. In the
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multicentre, cross-sectional study by van Ginkel et al., the
early treatment group consisted of pre-symptomatically
diagnosed patients (cascade testing or routine PKU
screening) with nitisinone started before 2 months of age
[19]. Comparisons were made with TYR1 patients with
‘late’ nitisinone treatment initiation after 4 weeks or
30 days of age in the Québec study (21 of 26 patients
were screen-detected but born prior nitisinone availability)
[10, 11]. In the Birmingham study and the multicentre
cross-sectional study, ‘late’ nitisinone treatment groups
consisted of clinically presenting patients with nitisinone
treatment started at 2–6 months or >6 months [17, 19], or
between 1.5 and 17 months of age [14], whereas Santra et
al. divided the symptomatically presenting cases by pheno-
type of liver disease at presentation (acute liver failure:
nitisinone started between 1 month and 2 years; chronic
liver disease: nitisinone started between 2 months and 9
years) [12]. Follow-up time in the cohort studies was on
average 6.2 years and 13.6 years in the early and late inter-
vention groups, respectively, in the analysis of the Québec
cohort by Simoncelli et al. [11], and between five and
11 years in the early treatment group and between two
and 19 years in the late treatment group in the analysis of
the Québec cohort by Larochelle et al. [10] (data estimated
by reviewers from bar chart only). Duration of follow-up
was between one and 10 years in one part of the Birming-
ham study [12], between three and 19 years in surviving
patients in another part of the Birmingham study [14], on
average 9.1 years (standard deviation 6.3 years) in the
international cohort [18] and not reported in a third paper
of the Birmingham study [17].
Quality appraisal
Using the EPHPP quality assessment tool for quantita-
tive studies [16], the overall methodological quality was
judged as moderate (one weak rating) in the Québec
study [10, 11], moderate to weak (one and three weak
ratings, respectively) in the Birmingham study [12, 14, 17],
and weak (three weak ratings each) in the international co-
hort [18] and the cross-sectional study [19] (see Table 2).
There was high risk of selection bias in the cross-sectional
study [19], the international cohort [18] and in one paper
Fig. 1 PRISMA flow diagram of records through the systematic review. *See Additional file 1 for list of excluded studies with reasons
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Table 1 Characteristics of included studies
Study Study design Participants Treatment
Birmingham cohort
Bartlett 2014 [17] Prospective cohort
Follow-up time NR
Study setting: Birmingham
Children’s Hospital, UK
Number of centres: 1
N = 38
TYR1 patients treated between 1989
and 2009.
Pre-NTBC: n = 7
Post-NTBC: n = 31
Age at presentation:
<2 months: n = 11
(6 detected by cascade testing,
4 incidental detection by routine
PKU screening,
1 symptomatic presentation)
2–6 months: n = 11
>6 months: n = 9
Pre-NTBC: Diet
Post-NTBC: NTBC and diet.
NTBC: Initial dose of 1 mg/kg
(0.6 mg/kg before 1995);
dose adjusted to clinical and
biochemical response (including plasma
and urinary SUAC) and plasma levels
thereafter (target 50 μmol/l).
Diet NR
McKiernan 2015 [14] Retrospective cohort
(sibling-controlled)
Age at last follow-up
Pre-clinically diagnosed:
3–12.5 years
Clinically diagnosed: 10–19 years
or death at 1.5 and 7 months,
respectively
Study setting: Birmingham
Children’s Hospital, UK
Number of centres: 1
N = 17
TYR1 patients treated pre-symptomatically
with NTBC following selective newborn
screening and their clinically presenting
siblings.
Pre-clinically diagnosed: n = 12
NTBC start: median 4 (range 2–52) days.
Clinically diagnosed siblings: n = 5
Age at presentation:
Median 4 (range 1.5–17) months.
NTBC and diet
NTBC: 1 mg/kg/day;
NTBC titrated according to body weight
until 10 kg, after which adjusted
according to blood NTBC
concentrations (3 monthly assessments).
Diet: Fat soluble vitamin
supplementation for at least 3 months.
Tyr and Phe restriction.
Breast feeding combined with Tyr and
Phe free protein substitute.
For formula fed infants, Tyr and Phe free
protein substitute with natural protein
requirements supplied as conventional
formula.
Dietary treatment titrated according to
blood Phe and Tyr levels
(3 monthly assessments).
Santra 2008 [12] Retrospective cohort
Follow-up: 1–10 years.
Study setting: Birmingham
Children’s Hospital, UK
Number of centres: 1
N = 21
TYR1 patients treated with NTBC for
at least 12 months.
Phenotype of liver disease at presentation:
Acute liver failure: n = 9
Age at presentation: Median 17 weeks
(range 1 month to 2 years).
Chronic liver disease: n = 7
Age at presentation: Median 60 weeks
(range 2 months to 9 years).
Pre-clinically: n = 5
Age at presentation: Median < 1 week
(range < 1 to 2 weeks).
NTBC and diet
NTBC: Standard protocol using
nitisinone dosing of 0.6 mg/kg before
1995 and 1 mg/kg since 1995, the dose
thereafter adjusted according to
response.
Diet: Normocaloric Tyr- and Phe-
restricted diet, fat-soluble vitamins in
the presence of liver dysfunction and
phosphate supplements during
hypophosphataemia.
Québec cohort
Larochelle 2012 [10] Cohort
(Before 1994 retrospective,
thereafter prospective data
collection)
Age at last follow-up (2009,
death or OLT)
No NTBC: OLT/death at
0.5–10 years;
>30 days: 9–19 years or
OLT/death at 2–8 years;
≤30 days: 5–11 years
(estimated by reviewers from
bar chart)
Study setting: Québec, Canada
Number of centres: NR
N = 78
TYR1 patients born 1984–2004.
No NTBC: n = 28
(777 patient months)
NTBC introduced
≤30 days: n = 24
(all detected by routine TYR1 screening)
(2593 patient months).
>30 days: n = 26
(21/26 detected by routine TYR1
screening)
(535 patient months pre-NTBC;
3138 patient months with NTBC).
No NTBC: Diet (see below)
Early- and Late-NTBC: NTBC and diet
NTBC: Initially fixed at 0.6 or 1.0 mg/kg
daily in 2 daily oral doses.
For the first 2 years of the study:
recrystallized preparation of NTBC.
Thereafter: commercially-produced
nitisinone.
After 1999: NTBC dose titrated in order
to minimise urine SUAC levels.
Diet: Dietary restriction of Phe and Tyr
aiming to maintain plasma Tyr at
200–400 μmol/L.
Simoncelli 2015 [11]
(supersedes Larochelle
et al. [10])
Retrospective cohort
Follow-up until death or
1 January 2009;
N = 95
TYR1 patients treated between 1984
and 2008.
No NTBC: n = 28
No NTBC: Diet and “curative” OLT.
Early- and Late-NTBC: NTBC and diet.
(NR, possibly as in Larochelle et al. [7])
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from the Birmingham study [14]. Dose of nitisinone and
dietary treatment varied within the multicentre studies
[18, 19] and between the studies. All four studies had a
high potential of confounding as important factors (i.e.
pre-existing health problems, presenting form of TYR1,
compliance with treatment, co-treatment) were not con-
trolled in study design or analysis. Length of follow-up dif-
fered between and within studies with usually higher age
at last follow-up of (surviving) late-treated patients in the
Birmingham [14, 17] and Québec [10, 11] cohort studies.
The applicability of the reported findings to the screening
context in our review question and to actual clinical prac-
tice is limited: none of the four included studies provided a
comparison of outcomes of nitisinone treatment following
TYR1 detection by universal newborn screening versus im-
mediate nitisinone initiation following symptomatic presen-
tation in an unscreened population. In the Québec study
[10, 11], all of the patients with TYR1 in the early treatment
group were identified by universal newborn screening but
patients with TYR1 in the late treatment group (after 1
month of age, n = 26) included 21 children (81%) who were
also screen-detected but diagnosed before nitisinone be-
came available and treated with diet and supportive treat-
ment only for up to 7 years. Only five patients in this group
presented clinically with symptoms and were treated with
nitisinone as soon as diagnosis was confirmed. In the UK-
based cohort and the cross-sectional study, all [12, 19], 10/
11 [17], and 11/12 [14] TYR1 patients in the early-treated
group, respectively, were identified by cascade testing or
during neonatal PKU screening and compared to patients
who presented clinically. One in five [14] and 1 in 9 [19]
patients included in the late-treated group, respectively,
were diagnosed before nitisinone became available. In the
international cohort study by Mayorandan et al. [18], it
was unclear if all patients in the early-treated group were
identified pre-symptomatically by newborn screening and
Table 1 Characteristics of included studies (Continued)
Age at study end date
(1 January 2009)
No NTBC: IQR 16.3–21.7 years
NTBC ≥4 weeks: IQR 12.6–15.0 years
NTBC <4 weeks: IQR 3.4–8.5 years
(p < 0.001, Kruskal-Wallis test)
Study setting: Québec, Canada
Number of centres: 5
NTBC introduced
<4 weeks: n = 41
Median 13 days (IQR 11–16 days)
(all detected by routine TYR1 screening).
≥4 weeks: n = 26
Median 1.0 years (IQR 0.4–2.2 years)
(21/26 detected by routine TYR1
screening)
International studies
Mayorandan 2014 [18] Retrospective cohort
(Retrospective data collected
via questionnaire)
Average follow-up time: 9.1
(SD 6.3) years.
Study setting: Europe, Turkey
and Israel.
Number of centres: 21
N = 168 included in study.
TYR1 patients with questionnaire data.
No NTBC: n = 10
NTBC: n = 154 (1157 patient years)
No data on treatment: n = 4
N = 148 NTBC-treated patients included
in analysis:
NTBC start:
<1 month: n = 37
(unclear if detected following screening
or symptomatically)
1–6 months: n = 45
7–12 months: n = 20
>12 months: n = 46
Varying NTBC and diet treatment
strategies between different centres.
NTBC (n = 154):
Initial NTBC dosage:
Mean 1.7 mg/kg/day (SD 0.5,
range 0.2–5)
Current maintenance therapy:
Mean 1.0 mg/kg/day (SD 0.3,
range 0.3–2)
1–3 doses per day, on average 2 doses
per day.
Diet: All patients received dietary
treatment in addition to NTBC.
Natural protein restriction or Phe and
Tyr calculation in 38%, natural protein
restriction or Tyr intake calculation in
19%, natural protein restriction only in
19%, and Tyr and Phe calculation in
24% of centres.
Van Ginkel 2016 [19] Cross-sectional
(retrospective and prospective
data collection)
Study setting: Netherlands,
Belgium, UK
Number of centres: NR
(multicentre)
N = 38 included in study
19 TYR1 patients and 19 age- and
gender matched healthy controls.
Included in subgroup analysis:
N = 17–19 TYR1 patients
Age at diagnosis
<2 months (pre-symptomatically):
n = 8–10
(detected by cascade testing or as
coincidence in routine PKU screening)
2–6 months: n = 6
>6 months: n = 3
NTBC and diet
Varying NTBC and diet treatment
strategies between different centres.
Diet: Phe and Tyr restricted.
Natural protein restriction.
Supplementation of all non-Phe and
non-Tyr amino acids provided with one
of the available amino acid mixtures
that contain neither Phe nor Tyr.
IQR interquartile range, NR not reported, NTBC 2-(2-nitro-4-trifluoromethylbenzoyl)-1,3-cyclohexanedione, nitisinone, OLT, orthotopic liver transplantation,
Phe phenylalanine, PKU phenylketonuria, SD standard deviation, SUAC succinylacetone, Tyr tyrosine, TYR1 Tyrosinemia type 1
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if late-treated patients were treated with nitisinone directly
after diagnosis.
Mortality rate
Four articles reported on comparisons of the mortality
rate between early and late nitisinone -treated TYR1 pa-
tients from the Québec cohort [10, 11], the Birmingham
cohort [14], and the international cohort [18]. Combined,
a total of 260 TYR1 patients (17 from the Birmingham
cohort, 95 from the Québec cohort, and 148 from the
international cohort) were included in the analyses. In
the Québec study, ten people (36%) who never received
nitisinone died at a median age of 1.1 years (interquar-
tile range [IQR] 0.6–2.1 years), two deaths (8%) due to
complications of liver transplantation occurred in the
late nitisinone-treated group at ages of 7.4 and 8.7 years;
none of the 24 people in the early nitisinone-treated
group had died after a follow-up time of 5–11 years
[10, 11]. There were significantly more deaths in the
never nitisinone-treated group than either the early or
late nitisinone-treated groups. Contrary to Larochelle
and colleagues, our analysis indicated no significant dif-
ference in death rates between the early and late
nitisinone-treated groups (p = 0.49 using Fisher exact
test). In the Birmingham cohort, no death (0/12) oc-
curred in the pre-symptomatically treated group after a
follow-up time of 3–12.5 years, while two of five clinic-
ally presenting infants died. (One was born prior to
nitisinone availability and died prior to liver transplant-
ation aged 1.5 months, the other was born at 25 weeks’
gestation and died from respiratory complications of
prematurity aged 7 months.) The age at last follow-up
of the three surviving patients was 10–19 years [14]. In
the international cohort, odds ratios (OR) for death
were not significantly different in patients diagnosed
and treated with nitisinone beyond the perinatal period
compared to those with treatment initiation before the
age of 1 month [18]. Age of patients at last follow-up
or length of follow-up was not reported by comparison
group. Only three deaths occurred among all 148
nitisinone-treated TYR1 patients (one patient was diag-
nosed and treated at the age of 5 years but died from
failure of the transplanted liver, and two patients with
treatment initiation between 7 and 12 months of age
died from hepatocellular carcinoma and metastasis).
Hepatic manifestations of TYR1 and requirement for liver
transplantation
Five articles reported on comparisons in hepatic mani-
festations of TYR1 and/or the requirement for orthoto-
pic liver transplantation (OLT) between early and late
nitisinone-treated patients from the Québec study [10,
11], the Birmingham study [14, 17] and the international
cohort [18] (see Table 3). The number of included pa-
tients ranged from 17 [14] to 148 [18]. In the Québec
study, OLT was performed in 20 patients (71%) in the
never nitisinone-treated group at a median age of
2.0 years (IQR 1.0–2.8 years), and in seven (27%) late
nitisinone-treated patients at a median age of 4.8 years
(IQR 2.9–7.6 years); no early nitisinone-treated patient
required OLT after 5–11 years of follow-up. Rates of
OLT were significantly lower amongst early and late
nitisinone-treated patients compared to those who were
never treated with nitisinone, and lower in those receiv-
ing early nitisinone treatment than late nitisinone treat-
ment [10, 11]. In the Birmingham study, six of the seven
(86%) never nitisinone-treated patients required OLT at
a median age of 61 months (range 19–126 months)
while only seven of the 31 (23%) nitisinone-treated
Table 2 Study quality of included studies according to EPHPP quality assessment tool [16]
Study Global rating from sections A-F Global rating
for this studyA) Selection bias B) Study design C) Confounders D) Blinding E) Data collection
methods
F) Withdrawals
and drop-outs
Québec study
Larochelle 2012 [10] Strong Moderate Weak Moderate Strong Strong Moderate
Simoncelli 2015 [11] Strong Moderate Weak Moderate Strong Strong Moderate
Birmingham study
Bartlett 2014 [17] Strong Moderate Weak Moderate Strong Strong Moderate
McKiernan 2015 [14] Weak Moderate Weak Moderate Weak Strong Weak
Santra 2008 [12] Moderate Moderate Weak Moderate Weak Weak Weak
International cohort
Mayorandan 2014 [18] Weak Moderate Weak Moderate Weak Strong Weak
Cross-sectional study
Van Ginkel 2016 [19] Weak Weak Weak Moderate Strong Strong Weak
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patients proceeded to OLT at a median age of 53 months
(range 5–163 months) (p = 0.004) [17]. No patient (0/11)
treated before 2 months of age, 3/11 (27%) patients pre-
senting between 2 and 6 months and 4/9 (44%) patients
presenting after 6 months of age subsequently underwent
OLT. The patient age at study end date was estimated
between 4.7–12.1 years, 7.8–21.2 years, and 9.0–23.2 years
for the <2 months, 2–6 months and >6 months com-
parison groups, respectively. Another analysis of the
Birmingham cohort by McKiernan et al. found that no
patient in the pre-symptomatically treated group (n = 12)
required OLT and all were reported as currently clinically
normal with no clinical, biochemical or radiological evi-
dence of liver disease aged 3–12.5 years at last follow-up
[14]. In the five clinically presenting siblings, one failed to
respond to nitisinone and underwent OLT at 5 months
and repeat OLT aged 15 for chronic rejection while the
other two surviving patients were clinically stable with
compensated liver disease aged 10 and 17. The inter-
national cohort study demonstrated significantly lower
rates of hepatocellular carcinoma, and requirements for
OLT in TYR1 patients with nitisinone started before 1
month of age versus nitisinone started after 12 months.
The study also demonstrated lower rates of acute liver dis-
ease and liver cirrhosis for those treated early (nitisinone
started before 1 month) versus nitisinone started at 7–
12 months. Hepatomegaly rates were also lower for those
treated before 1 month versus all late nitisinone-treated
groups [18].
Renal dysfunction and rickets
Two articles reported on renal dysfunction or rickets in
early- and late-treated TYR1 patients [12, 18]. There
were 148 patients included in the international cohort
and 21 in the Birmingham cohort. Santra et al. reported
that all TYR1 patients had proteinuria at presentation
with high values even in children who were diagnosed
pre-symptomatically [12]. Children presenting with acute
liver failure were more likely to be hypophosphataemic
(p < 0.01) and have excessive phosphaturia (p = 0.05) than
children who were diagnosed asymptomatically, while
children presenting with chronic hepatic and/or renal dys-
function had intermediate values. All three measured
markers of tubular dysfunction normalised within 1 year
of nitisinone treatment and remained normal at follow-up
of up to 10 years. No child redeveloped tubular dysfunc-
tion after starting on nitisinone treatment.
The international cohort study found higher rates of
renal dysfunction in TYR1 patients treated with nitisi-
none after 12 months of age (~24%, estimated from bar
chart) compared to treatment initiation before 1 month
of age (~7%, estimated from bar chart) (p < 0.05; OR
5.5; 95% confidence interval [CI] 1.1–26.6) [18]. Rickets
were more frequently observed in TYR1 patients with
nitisinone initiated after 12 months of age (~20%, esti-
mated from bar chart) compared to early treated patients
(no cases; p < 0.05; OR 19, 95% CI 1.1–338.3).
Hospital admissions
Two articles reported on the effect of early and late niti-
sinone treatment on hospitalisations in 78 and 95 TYR1
patients from Québec [10, 11]. Early nitisinone treat-
ment was associated with significant fewer hospital ad-
missions, in terms of both number of admissions per
person-year (0.83, 0.41, and 0.16 for never-nitisinone,
late-nitisinone, and early-nitisinone groups, respectively;
p < 0.001) and length of stay per person-year (7.6, 3.2, and
0.4 days, respectively; p < 0.001) [11]. The proportion of
patients with neurological crises was significantly different
between the three groups (14 [50%], 5 [19%], and 0 for
never-nitisinone, late-nitisinone, and early-nitisinone
groups, respectively; p < 0.001) [11]. No new acute hep-
atic or neurologic events occurred after the first dose of
nitisinone, even in late-treated patients [10].
Neurocognitive outcomes
Three articles reported on neurocognitive outcomes in
early and late nitisinone-treated patients; two cohort
studies [14, 18] and one cross-sectional study [19].
Seventeen patients were included in this analysis from
the Birmingham study [14], 17 to 19 in the cross-sec-
tional study [19] and 148 in the international cohort
[18]. In the Birmingham cohort, some degree of learn-
ing difficulty was observed in 4/9 pre-symptomatically
treated patients of school age [14]. All three surviving
siblings who were symptomatically treated required
extra educational support with one attending a specia-
lised secondary school due to learning difficulties.
Authors of the multicentre, cross-sectional study did
not identify any significant differences in reaction time
or percentage of errors in any of the neuropsycho-
logical tasks (intelligence quotient [IQ], executive
functioning, social cognition) when comparing TYR1
patients based on the age at diagnosis (<2 months,
n = 10; 2–6 months, n = 6; >6 months, n = 3) or
pre-symptomatically (n = 10) versus symptomatically
(n = 9) diagnosed patients [19]. While controlling for
age, the duration of nitisinone treatment was inversely
correlated with IQ (r = −0.51, p = 0.046) [19]. The
international cohort [18] observed impaired psycho-
motor development in 30/148 (20%), hyperactivity/at-
tention deficit syndrome or behavioural disorders in
12/148 (8%) and learning/language difficulties or dys-
lexia in 2/148 (1.4%) of all nitisinone-treated TYR1 pa-
tients. None of which were associated with time at
which nitisinone was initiated.
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Table 3 Liver disease and need for liver transplantation in early and late nitisinone-treated TYR1 patients
Study Study design Participants Outcome Age at last follow-up /
study end date
Birmingham study
Bartlett
2014 [17]
Cohort
(prospective data
collection)
N=38
No NTBC: n=7
NTBC: n=31
Age at presentation:
<2 months: n=11
2-6 months: n=11
>6 months: n=9
OLT
<2 months: 0/11 NR
2-6 months: 3/11 (27%) NR
>6 months: 4/9 (44%) NR
No NTBC: 6/7 (86%) NR
(p=0.004 vs 7/31 with NTBC)
Median age at NTBC start
No OLT: 52 (range 2-990) days;
OLT: 428 (range 86-821) days. (p=0.004)
McKiernan
2015 [14]
Cohort
(sibling-controlled,
retrospective data
collection)
N=17
Pre-clinically
diagnosed: n=12
Clinically diagnosed
siblings: n=5
OLT
Pre-clinically: 0/12 3-12.5 years;
Clinically: 1/5 (20%) 10-19 years or death
at 1.5 and 7 months,
respectively
Liver disease
Pre-clinically 0/12 3-12.5 years;
Clinically 2/3 (67%) surviving patients 10-19 years
Québec study
Larochelle
2012 [10]
Cohort
(Before 1994 retrospective,
thereafter prospective
data collection)
N=78
NTBC introduced
≤30 days: n=24
>30 days: n=26
No NTBC: n=28
UI
≤30 days: 0/24 5-11 years;
>30 days: 7/26 (27%) 9-19 years or OLT/death
at 2-8 years;
No NTBC: 20/28 (71%) OLT/death at 0.5-10 years
p < 0.001, ≤30 days vs No NTBC (Chi
square test); p < 0.001, >30 days vs
No NTBC (Chi square test); p = 0.010,
≤30 vs >30 days (Fisher exact test)a
Simoncelli
2015 [11]
Cohort
(Retrospective
data collection)
N=95
<4 weeks: n=41
≥4 weeks: n=26
No NTBC: n=28
Supersedes Larochelle
et al. [10]
OLT
<4 weeks: 0/41 IQR 3.4-8.5 years
≥4 weeks: 7/26 (27%) IQR 12.6-15.0 years
No NTBC: 20/28 (71%) IQR 16.3-21.7 years
(p<0.001, Fisher exact test) (p<0.001, Kruskal-Wallis test)
International cohort
Mayorandan
2014 [18]
International cohort
(retrospective data
collection via
questionnaire)
N=168 included in study.
N=148 NTBC-treated patients
included in analysis.
NTBC start:
<1 month: n=37
1-6 months: n=45
7-12 months: n=20
>12 months: n=46
OLT OR (95%CI)
>12 months: 12.7 (1.5-103)b NR
Acute liver
disease
<1 month: 0/37 NR
7-12 months: 3/20 (15%)* NR
Liver cancer OR (95%CI)
>12 months: 12.7 (1.5-103)b NR
Liver cirrhosis OR (95%CI)
7-12 months: 41.6 (2.2-779.9)b NR
>12 months: 40.5 (2.3-704.1)b NR
Hepatomegaly OR (95%CI)
1-6 months: 3.3 (0.9-11.3)b NR
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Post hoc comparisons
1) screen detected vs symptomatically detected patients,
direct nitisinone start after diagnosis
From the Québec study [10], we excluded 21 of 26 late-
treated patients as they were born prior to nitisinone
availability. This post hoc analysis considered 29 patients
with immediate nitisinone treatment following (1) de-
tection through screening (n = 24) and (2) symptomatic
detection (n = 5). No benefit of early nitisinone treatment
on mortality was observed in this post hoc analysis (no
deaths occurred in either the 24 screen-detected or five
symptomatically presenting cases). After the exclusion
of 26 TYR1 patients born prior to the nitisinone era,
benefits were observed of early nitisinone-treatment on
the need for OLT (0/24 screened vs 3/5 symptomatic-
ally presenting patients needed OLT) (see Table 4 for a
summary of initial and post hoc analyses results). While
the proportion of patients with neurological crises dif-
fered significantly between the three groups in the ini-
tial analysis (p < 0.001, Fisher exact test [11]), the post
hoc analysis did not demonstrate a difference in the
number of patients with neurological crises between
screen-detected and symptomatically presenting pa-
tients with immediate nitisinone treatment after diag-
nosis (no neurological crisis occurred in either groups).
No post hoc analysis was possible for number of hos-
pital admissions or days in hospital as individual pa-
tient data were not available.
Table 4 Summary of initial study results and post hoc analyses
Death Need for OLT Patients with neurological
crisis
Initial analysis
Early vs late
Québec cohort
Larochelle 2012 [10]
0/24 vs 2/26
(p = 0.49)a
Birmingham study McKiernan 2015 [14]
0/12 vs 2/5 (p = 0.07)
Québec cohort
Larochelle 2012 [10]
0/24 vs 7/26
(p = 0.01)a
Birmingham study
McKiernan 2015 [14]
0/12 vs 1/5 (p = 0.29)
Bartlett 2014 [17]
0/11 vs 7/20 (p = 0.033)
Québec cohort
Larochelle 2012 [10]
0/24 vs 5/26 (p = 0.051)
Simoncelli 2015 [11]
0/41 vs 5/26 (p = 0.007)
Post hoc 1
Screen detection vs symptomatic
detection, all with direct
nitisinone initiation
Québec cohort
Larochelle 2012 [10]
0/24 vs 0/5
Birmingham study McKiernan 2015 [14]
0/12 vs 1/4 (p = 0.25)
Québec cohort
Larochelle 2012 [10]
0/24 vs 3/5
(p = 0.0027)
Birmingham study McKiernan 2015 [14]
0/12 vs 1/4 (p = 0.25)
Bartlett 2014 [17]
0/10 vs 5/15 (p = 0.061)
Québec cohort
Larochelle 2012 [10]
0/24 vs 0/5
Simoncelli 2012 [11]
NA
Post hoc 2
Early symptomatic vs late
symptomatic,all with direct
nitisinone initiation
Québec cohort
Larochelle 2012 [10]
NA
Birmingham cohort
NA
Québec cohort
Larochelle 2012 [10]
NA
Birmingham cohort McKiernan 2015 [14]
NA
Bartlett 2014 [17]
0/1 vs 5/14
Québec cohort
NA
Post hoc 3
Screen detection, direct nitisinone
initiation vs screen detection,
1–12 months delayed nitisinone
initiation
Québec cohort
Larochelle 2012 [10]
0/24 vs 0/10
Birmingham cohort
NA
Québec cohort
Larochelle 2012 [10]
0/24 vs 0/10
Birmingham cohort McKiernan 2015 [14]
NA
Bartlett 2014 [17]
NA
Québec cohort
Larochelle 2012 [10]
0/24 vs 1/10 (p = 0.294)
Simoncelli 2015 [11]
NA
aBased on our analysis of data presented in the paper by Larochelle et al. [10] using Fisher exact test
NA not applicable, OLT Orthotopic liver transplantation
Table 3 Liver disease and need for liver transplantation in early and late nitisinone-treated TYR1 patients (Continued)
7-12 months: 4.4 (1.1-17.7)b NR
>12 months: 3.9 (1.1-13.3)b NR
Odds/rates for not presented late-treated
groups were not significantly different
compared to early NTBC (<1 month).
aBased on our analysis of data presented in the paper by Larochelle et al. [10] using Fisher exact test. b <1 month: OR = 1. * p <0.05 vs <1 month
CI confidence interval, IQR interquartile range, NR not reported, NTBC nitisinone, OLT orthotopic liver transplantation, OR odds ratio
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The Birmingham cohort included small numbers for
this post hoc analysis, which are reported in Table 4.
No post hoc analysis was possible for the data presented
by Santra et al. [12], for the international cohort by
Mayorandan et al. [18] or the multicentre, cross-sectional
study [19], as individual patient data on diagnostic pro-
cedures, delay in nitisinone initiation and/or clinical
outcomes were not presented in these papers.
2) early symptomatic vs late symptomatic detection, direct
nitisinone start after diagnosis
This analysis was only possible using the Birmingham
study [17], and included small numbers. We excluded 10
screen-detected patients as well as six patients present-
ing symptomatically prior to the availability of nitisinone
(n = 3) or with delayed nitisinone treatment for other
(unknown) reasons (n = 3). This post hoc comparison
therefore considered one case presenting early with
symptoms at the age of 1 month and 14 patients pre-
senting with symptoms after 2 months of age, all were
treated with nitisinone immediately after diagnosis. The
patient presenting early with symptoms did not require
OLT after follow-up of 7.5 years, while 5/14 (36%) of the
patients presenting later (≥2 months) with symptoms
proceeded to OLT at a median age of 3.3 years (range
0.4–13.6 years).
3) direct vs 1–12 months delayed nitisinone initiation in
screen-detected patients
For this comparison, we used all screen-detected patients
from the Québec study [10] who started nitisinone within
the first month of life (n = 24) or within a time frame that
most patients present symptomatically (1–12 months,
n = 10). We excluded 16/26 patients from the late-treated
group as they were not screen-detected (n = 5) or nitisi-
none was initiated after 12 months of age (n = 11). No
deaths occurred in either of the direct or delayed treat-
ment groups, and no patients in the either group needed
OLT. None of the patients directly treated with nitisinone
had a neurological crisis, 1/10 (10%) of the patients with
delayed nitisinone-treatment had a neurological crisis,
which occurred before nitisinone initiation.
Discussion
We examined the clinical outcomes for people with TYR1
who received early treatment with nitisinone (when they
were pre-symptomatic) versus late treatment (after pre-
senting with symptoms). Four studies (published in seven
papers; three cohort studies and one cross-sectional study)
provided data on clinical outcomes. Results from Canada
[10, 11], England [14, 17] and an international cohort
study [18] suggest an association between earlier nitisi-
none treatment and lower rates of liver-related sequelae
and liver transplantation, but no effect on mortality.
However, all of the comparisons are subject to signifi-
cant bias. Our post-hoc analysis to control for some of
the confounding where possible could not replicate the
same effects. The effects of early versus later nitisinone
treatment on cognitive outcomes were inconsistent across
studies. No significant differences in cognition were found
between treatment groups in the international cohort [18]
and the multicentre, cross-sectional study [19], and no
benefits of early treatment with nitisinone was reported
for learning difficulties in a small subgroup of the Bir-
mingham cohort [14] (no statistical test was performed).
An observed negative correlation between duration of
nitisinone treatment and IQ [19] might indicate a possible
detrimental effect on cognitive outcomes.
A clear understanding of the potential benefits of earlier
treatment with nitisinone is difficult to ascertain because
of limitations in the evidence base. First, all of the studies
we identified were of observational design. There are
numerous methodological issues associated with obser-
vational studies including selection bias, lack of control
of participant characteristics, and absence of compara-
tor treatments. Second, sample sizes were often small
and participant populations heterogeneous, which limit
the generalizability of results. Third, there are concerns
regarding the applicability of the findings to the screen-
ing context in our review question and to actual clinical
practice as none of the four included studies provided a
comparison of clinical outcomes of early nitisinone
treatment following universal newborn screening using
SUAC as primary marker versus immediate treatment
with nitisinone following symptomatic presentation in
unscreened children. These types of limitations are in-
herent in research into rare diseases, and it is import-
ant to bear in mind that TYR1 is a very rare disease
(the total number of TYR1 patients treated with nitisi-
none in Europe is fewer than 400 [18]). This raises im-
portant questions about research with people who have
rare diseases. For example, what level of evidence do
we require, and how do we deal with bias in small obser-
vational studies? Gagne and colleagues [20] have reviewed
methods for generating evidence on health outcomes
for people who have rare diseases, and identified two
broad approaches to meeting these challenges. The first
approach focusses on study designs that keep the total
number of participants to a minimum. The second ap-
proach is to employ designs that maximise the number
of participants who receive the study treatment, such
as crossover and N-of-1 trials (which enable all partici-
pants to receive treatment). Bogaerts and colleagues
[21] have also suggested a range of alternatives, including
an increased tolerance for type 1 errors, and employing
Bayesian designs (focusing on estimation rather than
hypothesis testing).
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Our systematic review has a number of strengths. We
conducted a wide ranging and exhaustive systematic
searches without date limit, obtained expert input, and
two reviewers conducting all processes (literature screen-
ing, data extraction and quality assessment). However,
there are also some limitations. First, we excluded articles
not available in the English language; non-English-
language papers may be available and add further infor-
mation. Second, the exclusion criteria of our post hoc ana-
lyses were not pre-specified in the protocol and the results
should be interpreted with caution. Third, the information
used in our post hoc analysis was estimated for two stud-
ies; delay of nitisinone treatment from a bar chart (see fig-
ure two in Larochelle et al. [10]), and a table (see table two
in Bartlett et al. [17]).
A previous rapid review of screening for TYR1 con-
cluded that nitisinone is an effective treatment and that
it leads to better outcomes when initiated early [22]. At
the time of this review, the only published literature on
earlier versus later treatment with nitisinone was the
Canadian cohort study of Larochelle et al. [10]. The re-
sults of our full systematic review, which included an
additional three studies, are broadly consistent with this.
However, we have identified issues with the evidence
base that temper any conclusions about whether earlier
treatment is more beneficial than later treatment.
To our knowledge, this is the first systematic review that
provides a synthesis of all of the available studies that have
compared the outcomes of TYR1 patients with early (pre-
symptomatic) nitisinone treatment to later nitisinone-
treated (symptomatically presenting) patients to assess the
question of early treatment benefit from a screening per-
spective. Adequate evidence is still very limited. Further in-
vestigation is needed regarding whether the TYR1 cases
detected by screening represent the same spectrum of dis-
ease as those detected symptomatically and whether it is
certain that all screen-detected babies would become symp-
tomatic in the absence of screening. Evidence is needed on
whether improved outcomes with early administration of
nitisinone are due to the effectiveness of the drug, differ-
ences in the spectrum of disease or other confounding fac-
tors. Observational research is very valuable for rare
diseases, particularly where international collaboration pro-
duces increased sample sizes, but efforts must be made to
adjust for confounders if results are to be interpreted
meaningfully.
Conclusions
Nitisinone appears to be an effective treatment for
TYR1. There is some evidence that liver transplants are
less common amongst individuals who receive treatment
during the first 2 months of life than those who receive
it later. This is supported by post hoc comparisons
attempting to control for the effect of confounders and
addressing applicability issues. Further research is needed
to strengthen the evidence base and confirm the benefit of
pre-emptive nitisinone treatment.
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